Figure 7.
Anti-SARS-CoV-2 spike IgG levels post vaccination in serum samples from cancer and healthy cohorts within different sex groups. Comparison of serum anti-spike IgG levels in healthy, multiple myeloma, non-MM hematological cancer and solid cancer cohorts within different sex groups 1-month (A) and 6-months (B) post-vaccination. Anti-spike IgG levels were presented as Geometric Mean (GM) with 95% confidence intervals (95% CI). Box plots show median (horizontal bar), the first and third quartiles. Differences assessed by non-parametric Wilcoxon rank sum test. *p<0.05, **p<0.01.
